INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
May 01, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 20,120 | $134.54 | 845,986 |
May 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Open market or private sale of non-derivative or derivative security | 9,851 | $977.42 | 848,105 |
May 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Open market or private sale of non-derivative or derivative security | 6,885 | $976.56 | 857,956 |
Dec 14, 2011 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 38,516 | $51.18 | 860,754 |
May 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Open market or private sale of non-derivative or derivative security | 5,225 | $975.60 | 864,841 |
May 01, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $133.95 | 866,106 |
Mar 26, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 1,010 | $121.09 | 866,206 |
Mar 26, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 32,140 | $120.21 | 867,216 |
May 15, 2024 |
Director, Bd. Co-Chair, President & CSO
|
Director, Bd. Co-Chair, President & CSO | Form 4 | Open market or private sale of non-derivative or derivative security | 4,778 | $974.47 | 870,066 |
Dec 14, 2010 |
Director, EVP CSO & Pres Regn Res Labs
|
Director, EVP CSO & Pres Regn Res Labs | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 250,000 | -- | 870,375 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.